(2015). Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol.
Chicago Style Citation"Denosumab for the Prevention of Skeletal Complications in Metastatic Castration-resistant Prostate Cancer: Comparison of Skeletal-related Events and Symptomatic Skeletal Events." Ann Oncol 2015.
Cita MLA"Denosumab for the Prevention of Skeletal Complications in Metastatic Castration-resistant Prostate Cancer: Comparison of Skeletal-related Events and Symptomatic Skeletal Events." Ann Oncol 2015.
Atenció: Aquestes cites poden no estar 100% correctes.